Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High Concordance of Gene Expression Profiling–correlated Immunohistochemistry Algorithms in Diffuse Large B-cell Lymphoma, Not Otherwise Specified

4 Apr 2014

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is classified into prognostically distinct germinal center B-cell (GCB) and activated B-cell subtypes by gene expression profiling (GEP). Recent reports suggest the role of GEP subtypes in targeted therapy. Immunohistochemistry (IHC) algorithms have been proposed as surrogates of GEP, but their utility remains controversial. Using microarray, we examined the concordance of 4...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Cutaneous lymphoproliferative disorders research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24705314
DOI: 10.1097/pas.0000000000000211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High Concordance of Gene Expression Profiling–correlated Immunohistochemistry Algorithms in Diffuse Large B-cell Lymphoma, Not Otherwise SpecifiedPMID 24705314Read ↗

Biological heterogeneity in diffuse large B-cell lymphomaSemantic proximity Read ↗

Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profilingSemantic proximity Read ↗

Incremental value in outcome prediction with gene expression–based signatures in diffuse large B-cell lymphomaSemantic proximity Read ↗

Improved Personalized Survival Prediction of Patients With Diffuse Large B-cell Lymphoma Using Gene Expression ProfilingSemantic proximity Read ↗

Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded TissuesSemantic proximity Read ↗

Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?Semantic proximity Read ↗

Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.Semantic proximity Read ↗

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With RituximabSemantic proximity Read ↗

Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.Semantic proximity Read ↗

Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise SpecifiedSemantic proximity Read ↗

Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell LymphomaSemantic proximity Read ↗

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.